Eclosion Ventures manages the Eclosion life science investment fund, which focuses on translating cutting edge science into biotechnology companies developing transformational best-in-diseases therapeutics and platform technologies.
We are builders
Eclosion’s approach is defined by its unique entrepreneurial mindset leading to a strong operational and investment commitment to start-up enterprises. Eclosion is driven by an experienced management team which brings together scientific, operational and financial expertise and a successful track record of company creation, value generation and development of new therapeutics that will transform human healthcare.
We focus on highly innovative science
and early stage companies developing new approaches to address high unmet medical needs. Eclosion2 fund’s portfolio companies have developed first-in-class drugs with high potential value to patients in fields such as multiple sclerosis, fibrosis or oncology.
We are enablers
Eclosion private investment fund supports portfolio companies from seed to capital stage up to clinical proof of concept, making significant long term operational and financial commitments to companies that have the potential to change the way patients are treated.
Board of Directors
Bertrand Reich (Chairman) ; Claude Bertrand ; Roman Fleck ; Benoît Habert ; Isaac Kholberg ; Dr. Andrew Parker ; Alessia Torricelli
Dr. Jacques Mizrahi
World’s Premier biotechnology company developing a novel approach in oncology targeting dependence Receptors and their ligand, including Netrin-1 with specific impact on the Epithelial-to-Mesenchymal Transition process.